In this episode, Brandon speaks with Dina Burkitbayeva, CEO of Freedom Biosciences and co-founder of PsyMed Ventures, about the evolving landscape of mental health innovation. Dina shares how a lack of dedicated mental health investment led her to launch one of the first venture funds focused on psychedelic and neurotechnology-based treatments. She discusses Freedom’s lead program, a ketamine-rapamycin combination that could extend the duration of ketamine’s effects and ease the treatment burden for patients with severe depression. We explore the rise of interventional psychiatry and how next-gen treatments could transform access and outcomes. Dina also calls for faster, more collaborative regulatory processes to support biotech innovation in high-need areas.
Related Podcasts
Subscribe to Power's Newsletter
Stay ahead with a new patient recruitment insight every week.